Swiss Medical Weekly - Immune thrombocytopenia associated with COVID-19 mRNA vaccine tozinameran – a clinical case and global pharmacovigilance data
Swiss biotech innovation: global power and impact through diversity – Swiss Biotech
Building a biotech hub: Switzerland focuses on mRNA, CGT and more
mRNA Vaccines: Possible Tools to Combat SARS-CoV-2 | SpringerLink
Will an mRNA vaccine alter my DNA? | Gavi, the Vaccine Alliance
Vaccines | Free Full-Text | An Update on Self-Amplifying mRNA Vaccine Development | HTML
Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients | Journal for ImmunoTherapy of Cancer
Vaccines | Free Full-Text | mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients | HTML
Protection duration after vaccination or infection – Swiss National COVID-19 Science Task Force
How mRNA Technology Gave Us the First COVID-19 Vaccines | Time
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates | npj Vaccines
Swiss Medical Weekly - The very low risk of myocarditis and pericarditis after mRNA COVID-19 vaccination should not discourage vaccination
How vaccine technology, choice and supply work in Switzerland - SWI swissinfo.ch
Vaccines | Free Full-Text | SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond | HTML
mRNA vaccine - Wikipedia
Behind the Science: what is an mRNA Vaccine? | Pfizer UK
Switzerland backs mRNA vaccine for booster jabs - SWI swissinfo.ch
Frontiers | RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics? | Immunology
4 things about mRNA COVID vaccines researchers still want to find out | Gavi, the Vaccine Alliance
Vaccines | Free Full-Text | An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
Vaccines | Free Full-Text | Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans | HTML
Design und Funktionsweise von mRNA-basierten Impfstoffen zum Schutz vor Infektionskrankheiten (COVID-19-Update) - Trillium GmbH Medizinischer Fachverlag
BNT162b2 mRNA COVID-19 Vaccine: First Approval | SpringerLink
